148 related articles for article (PubMed ID: 11026652)
1. Inhibition of vascular endothelial growth factor activity by transfection with the soluble FLT-1 gene.
Chen H; Ikeda U; Shimpo M; Maeda Y; Shibuya M; Ozawa K; Shimada K
J Cardiovasc Pharmacol; 2000 Oct; 36(4):498-502. PubMed ID: 11026652
[TBL] [Abstract][Full Text] [Related]
2. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity.
He Y; Smith SK; Day KA; Clark DE; Licence DR; Charnock-Jones DS
Mol Endocrinol; 1999 Apr; 13(4):537-45. PubMed ID: 10194760
[TBL] [Abstract][Full Text] [Related]
3. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation.
Clark DE; Smith SK; He Y; Day KA; Licence DR; Corps AN; Lammoglia R; Charnock-Jones DS
Biol Reprod; 1998 Dec; 59(6):1540-8. PubMed ID: 9828203
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.
Bussolati B; Dunk C; Grohman M; Kontos CD; Mason J; Ahmed A
Am J Pathol; 2001 Sep; 159(3):993-1008. PubMed ID: 11549592
[TBL] [Abstract][Full Text] [Related]
5. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review.
Ahmed A; Dunk C; Ahmad S; Khaliq A
Placenta; 2000; 21 Suppl A():S16-24. PubMed ID: 10831117
[TBL] [Abstract][Full Text] [Related]
6. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2.
Roeckl W; Hecht D; Sztajer H; Waltenberger J; Yayon A; Weich HA
Exp Cell Res; 1998 May; 241(1):161-70. PubMed ID: 9633524
[TBL] [Abstract][Full Text] [Related]
7. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1.
Barleon B; Totzke F; Herzog C; Blanke S; Kremmer E; Siemeister G; Marmé D; Martiny-Baron G
J Biol Chem; 1997 Apr; 272(16):10382-8. PubMed ID: 9099677
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization.
Lai CM; Brankov M; Zaknich T; Lai YK; Shen WY; Constable IJ; Kovesdi I; Rakoczy PE
Hum Gene Ther; 2001 Jul; 12(10):1299-310. PubMed ID: 11440623
[TBL] [Abstract][Full Text] [Related]
9. Identification of a vascular endothelial growth factor (VEGF) antagonist, sFlt-1, from a human hematopoietic cell line NALM-16.
Inoue T; Kibata K; Suzuki M; Nakamura S; Motoda R; Orita K
FEBS Lett; 2000 Mar; 469(1):14-8. PubMed ID: 10708747
[TBL] [Abstract][Full Text] [Related]
10. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma.
Shiose S; Sakamoto T; Yoshikawa H; Hata Y; Kawano Y; Ishibashi T; Inomata H; Takayama K; Ueno H
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2395-403. PubMed ID: 10937546
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells.
Barleon B; Siemeister G; Martiny-Baron G; Weindel K; Herzog C; Marmé D
Cancer Res; 1997 Dec; 57(23):5421-5. PubMed ID: 9393770
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor and soluble FLT-1 receptor interactions and biological implications.
Malecki M; Trembacz H; Szaniawska B; Przybyszewska M; Janik P
Oncol Rep; 2005 Dec; 14(6):1565-9. PubMed ID: 16273257
[TBL] [Abstract][Full Text] [Related]
13. Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.
Shibuya M; Seetharam L; Ishii Y; Sawano A; Gotoh N; Matsushime H; Yamaguchi S
Princess Takamatsu Symp; 1994; 24():162-70. PubMed ID: 8983073
[TBL] [Abstract][Full Text] [Related]
14. Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function.
Wang JF; Milosveski V; Schramek C; Fong GH; Becks GP; Hill DJ
J Endocrinol; 1998 Apr; 157(1):5-12. PubMed ID: 9614352
[TBL] [Abstract][Full Text] [Related]
15. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.
Boocock CA; Charnock-Jones DS; Sharkey AM; McLaren J; Barker PJ; Wright KA; Twentyman PR; Smith SK
J Natl Cancer Inst; 1995 Apr; 87(7):506-16. PubMed ID: 7707437
[TBL] [Abstract][Full Text] [Related]
16. Luteal angiogenesis: prevention and intervention by treatment with vascular endothelial growth factor trap(A40).
Wulff C; Wilson H; Rudge JS; Wiegand SJ; Lunn SF; Fraser HM
J Clin Endocrinol Metab; 2001 Jul; 86(7):3377-86. PubMed ID: 11443214
[TBL] [Abstract][Full Text] [Related]
17. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.
Meyer M; Clauss M; Lepple-Wienhues A; Waltenberger J; Augustin HG; Ziche M; Lanz C; Büttner M; Rziha HJ; Dehio C
EMBO J; 1999 Jan; 18(2):363-74. PubMed ID: 9889193
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells.
Kanellis J; Fraser S; Katerelos M; Power DA
Am J Physiol Renal Physiol; 2000 Jun; 278(6):F905-15. PubMed ID: 10836978
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid-induced angiogenesis is VEGF-dependent.
Carter WB; Uy K; Ward MD; Hoying JB
Surgery; 2000 Sep; 128(3):458-64. PubMed ID: 10965318
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis.
Zhao Q; Egashira K; Inoue S; Usui M; Kitamoto S; Ni W; Ishibashi M; Hiasa Ki K; Ichiki T; Shibuya M; Takeshita A
Circulation; 2002 Mar; 105(9):1110-5. PubMed ID: 11877364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
